Table 2.

Visual Acuity Outcomes for Endophthalmitis After Intravitreal Anti–Vascular Endothelial Group Factor Injection in the Face Mask Group vs No Talking Group

	Face Mask Group (N = 9)	“No Talking” Group (N = 168)	P Value
Mean logMAR VA at causative injection	0.46	0.61	.453
Mean logMAR VA at endophthalmitis presentation	1.51	2.01	.08
Average lines of Snellen VA lost from baseline	10.4 lines	14.0 lines	.114
Mean logMAR VA at 6 months	0.84	1.06	.500
Average lines of Snellen VA lost from baseline at 6 months	3.8 lines	4.5 lines	.783
Three lines or more of Snellen VA lost from baseline at 6 months, n (%)	3 (33%)	63 (40%)	.685
VA of CF or worse at 6 months, n (%)	0 (0%)	24 (15%)	.205
Mean logMAR VA at last follow-up	1.08	1.17	.793
Average lines of Snellen VA lost from baseline at last follow-up	6.2 lines	5.6 lines	.838
Three lines or more of Snellen VA lost from baseline at last follow-up, n (%)	6 (67%)	80 (48%)	.273
VA of CF or worse at last follow-up, n (%)	1 (11%)	36 (22%)	.454

CF = count fingers; VA = visual acuity.